Tryptophan, neurodegeneration and HIV-associated neurocognitive disorder

International Journal of Tryptophan Research

Volumn 3, Issue 1, 2010, Pages 121-140

  Davies, Nicholas W S ^a   Guillemin, Gilles ^a   Brew, Bruce J ^a  

^a ST VINCENT S HOSPITAL   (Australia)

Author keywords

HIV; Indoleamine 2,3 dioxygenase; Kynurenine pathway; Neurodegeneration; Tryptophan

Indexed keywords

EID: 84859577726     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/ijtr.s4321     Document Type: Review

References (229)

1. Ruddick JP, Evans AK, Nutt DJ, Lightman SL, Rook GA, Lowry CA. Tryptophan metabolism in the central nervous system: medical implications. Expert Rev Mol Med. 2006;8:1-27.
2. Fernstrom JD, Fernstrom MH. Exercise, serum free tryptophan, and central fatigue. J Nutr. 2006;136:553S-9S.
3. Pardridge WM, Fierer G. Transport of tryptophan into brain from the circulating, albumin-bound pool in rats and in rabbits. J Neurochem. 1990;54:971-6.
4. Smith QR, Momma S, Aoyagi M, Rapoport SI. Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem. 1987;49:1651-8.
5. Kennett GA, Curzon G, Hunt A, Patel AJ. Immobilization decreases amino acid concentrations in plasma but maintains or increases them in brain. J Neurochem. 1986;46:208-12.
6. O'Kane RL, Hawkins RA. Na+-dependent transport of large neutral amino acids occurs at the abluminal membrane of the blood-brain barrier. Am J Physiol Endocrinol Metab. 2003;285:E1167-73.
7. Knapp S, Mandell AJ. Narcotic drugs: effects on the serotonin biosynthetic systems of the brain. Science. 1972;177:1209-11.
8. Herrero E, Aragon MC, Gimenez C, Valdivieso F. Tryptophan transport into plasma membrane vesicles derived from rat brain synaptosomes. J Neurochem. 1983;40:332-7.
9. Gutierrez CI, Urbina M, Obregion F, Glykys J, Lima L. Characterization of tryptophan high affinity transport system in pinealocytes of the rat. Day-night modulation. Amino Acids. 2003;25:95-105.
10. Kaper T, Looger LL, Takanaga H, Platten M, Steinman L, Frommer WB. Nanosensor detection of an immunoregulatory tryptophan influx/kynurenine efflux cycle. PLoS Biol. 2007;5:e257.
11. Zhu L, Ji F, Wang Y, et al. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol. 2006;177:8226-33.
12. Boasso A, Herbeuval JP, Hardy AW, Winkler C, Shearer GM. Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood. 2005;105:1574-81.
13. Fleckner J, Martensen PM, Tolstrup AB, Kjeldgaard NO, Justesen J. Differential regulation of the human, interferon inducible tryptophanyltRNA synthetase by various cytokines in cell lines. Cytokine. 1995;7:70-7.
14. Reiter RJ, Tan DX, Jou MJ, Korkmaz A, Manchester LC, Paredes SD. Biogenic amines in the reduction of oxidative stress: melatonin and its metabolites. Neuro Endocrinol Lett. 2008;29:391-8.
15. Srinivasan V, Spence DW, Trakht I, Pandi-Perumal SR, Cardinali DP, Maestroni GJ. Immunomodulation by melatonin: its significance for seasonally occurring diseases. Neuroimmunomodulation. 2008;15:93-101.
16. Shedpure M, Pati AK. The pineal gland: structural and functional diversity. Indian J Exp Biol. 1995;33:625-40.
17. Waldhauser F, Ehrhart B, Forster E. Clinical aspects of the melatonin action: impact of development, aging, and puberty, involvement of melatonin in psychiatric disease and importance of neuroimmunoendocrine interactions. Experientia. 1993;49:671-81.
18. Karasek M, Winczyk K. Melatonin in humans. J Physiol Pharmacol. 2006;57 Suppl 5:19-39.
19. Pappolla MA, Chyan YJ, Poeggeler B, et al. An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease. J Neural Transm. 2000;107:203-31.
20. Tapias V, Cannon JR, Greenamyre JT. Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model. J Neurosci Res. 2009.
21. Fuller RW, Wong DT. Serotonin uptake and serotonin uptake inhibition. Ann N Y Acad Sci. 1990;600:68-78; discussion 79-80.
22. Furness JB, Costa M. Neurons with 5-hydroxytryptamine-like immunoreactivity in the enteric nervous system: their projections in the guinea-pig small intestine. Neuroscience. 1982;7:341-9.
23. Jonnakuty C, Gragnoli C. What do we know about serotonin? J Cell Physiol. 2008;217:301-6.
24. Bellivier F, Leboyer M, Courtet P, et al. Association between the tryptophan hydroxylase gene and manic-depressive illness. Arch Gen Psychiatry. 1998;55:33-7.
25. Lucki I. The spectrum of behaviors influenced by serotonin. Biol Psychiatry. 1998;44:151-62.
26. Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology. 2001;24:467-77.
27. Schroecksnadel K, Sarcletti M, Winkler C, et al. Quality of life and immune activation in patients with HIV-infection. Brain Behav Immun. 2008;22:881-9.
28. Lamoury FMJ, Lamoury J, Brew BJ. Interferon-β1B and cytokines alter the kynurenine pathway in mesenchymal stem cells. In World Congress of Neuroscience, July 12-17, Melbourne, Australia; 2007.
29. Mellor AL, Baban B, Chandler P, et al. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol. 2003;171:1652-5.
30. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol. 2004;4:762-74.
31. Guillemin GJ, Cullen KM, Lim CK, et al. Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007;27:12884-92.
32. Owe-Young R, Webster NL, Mukhtar M, et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance & neurotoxicity. J Neurochem. 2008.
33. Fujiwara M, Shibata M, Watanabe Y, et al. Indoleamine 2,3-dioxygenase. Formation of L-kynurenine from L-tryptophan in cultured rabbit fineal gland. J Biol Chem. 1978;253:6081-5.
34. Ball HJ, Sanchez-Perez A, Weiser S, et al. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene. 2007;396:203-13.
35. Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood. 2008;111:2152-4.
36. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002;1:609-20.
37. Pemberton LA, Stone E, Price P, van Bockxmeer F, Brew BJ. The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med. 2008;9:677-80.
38. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312-9.
39. Botting NP. Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism. Chemical Society Reviews. 1995;24:401-&.
40. Gal EM, Sherman AD. L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem Res. 1980;5:223-39.
41. Mangoni A. The "kynurenine shunt" and depression. Adv Biochem Psychopharmacol. 1974;11:293-8.
42. Badawy AA, Morgan CJ, Dacey A, Stoppard T. The effects of lofepramine and desmethylimipramine on tryptophan metabolism and disposition in the rat. Biochem Pharmacol. 1991;42:921-9.
43. Badawy AA, Morgan CJ. Effects of acute paroxetine administration on tryptophan metabolism and disposition in the rat. Br J Pharmacol. 1991;102:429-33.
44. Bano S, Sherkheli MA. Inhibition of tryptophan-pyrrolase activity and elevation of brain tryptophan concentration by fluoxetine in rats. J Coll Physicians Surg Pak. 2003;13:5-10.
45. Badawy AAB, Morgan CJ, Bano S, Buckland P, McGuffin P. Mechanism of enhancement of rat brain serotonin synthesis by acute fluoxetine administration. Journal of Neurochemistry. 1996;66:436-7.
46. Badawy AA, Evans M. Inhibition of rat liver tryptophan pyrrolase activity and elevation of brain tryptophan concentration by acute administration of small doses of antidepressants. Br J Pharmacol. 1982; 77:59-67.
47. Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56:2007-17.
48. Christensen HN. Organic ion transport during seven decades. The amino acids. Biochim Biophys Acta. 1984;779:255-69.
49. Joseph MH, Baker HF, Lawson AM. Positive identification of kynurenine in rat and human brain [proceedings]. Biochem Soc Trans. 1978;6:123-6.
50. Sas K, Csete K, Vecsei L, Papp JG. Effect of systemic administration of L-kynurenine on corticocerebral blood flow under normal and ischemic conditions of the brain in conscious rabbits. J Cardiovasc Pharmacol. 2003;42:403-9.
51. Sas K, Robotka H, Toldi J, Vecsei L. Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders. J Neurol Sci. 2007;257:221-9.
52. Alberati-Giani D, Ricciardi-Castagnoli P, Kohler C, Cesura AM. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J Neurochem. 1996;66:996-1004.
53. Heales SJ, Bolanos JP, Stewart VC, Brookes PS, Land JM, Clark JB. Nitric oxide, mitochondria and neurological disease. Biochim Biophys Acta. 1999;1410:215-28.
54. Ghafourifar P, Cadenas E. Mitochondrial nitric oxide synthase. Trends Pharmacol Sci. 2005;26:190-5.
55. Eastman CL, Guilarte TR. Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res. 1989;495:225-31.
56. Eastman CL, Guilarte TR. The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem Res. 1990;15:1101-7.
57. Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998;70:299-307.
58. Nakagami Y, Saito H, Katsuki H. 3-Hydroxykynurenine toxicity on the rat striatum in vivo. Jpn J Pharmacol. 1996;71:183-6.
59. Hiraku Y, Inoue S, Oikawa S, et al. Metal-mediated oxidative damage to cellular and isolated DNA by certain tryptophan metabolites. Carcinogenesis. 1995;16:349-56.
60. Stone TW, Forrest CM, Mackay GM, Stoy N, Darlington LG. Tryptophan, adenosine, neurodegeneration and neuroprotection. Metab Brain Dis. 2007;22:337-52.
61. Schuck PF, Tonin A, da Costa Ferreira G, et al. Kynurenines impair energy metabolism in rat cerebral cortex. Cell Mol Neurobiol. 2007;27:147-60.
62. Guidetti P, Amori L, Sapko MT, Okuno E, Schwarcz R. Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem. 2007;102:103-11.
63. Du F, Schmidt W, Okuno E, Kido R, Kohler C, Schwarcz R. Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol. 1992;321:477-87.
64. Knyihar-Csillik E, Okuno E, Vecsei L. Effects of in vivo sodium azide administration on the immunohistochemical localization of kynurenine aminotransferase in the rat brain. Neuroscience. 1999;94:269-77.
65. Kapoor R, Okuno E, Kido R, Kapoor V. Immuno-localization of kynurenine aminotransferase (KAT) in the rat medulla and spinal cord. Neuroreport. 1997;8:3619-23.
66. Kiss C, Ceresoli-Borroni G, Guidetti P, Zielke CL, Zielke HR, Schwarcz R. Kynurenate production by cultured human astrocytes. J Neural Transm. 2003;110:1-14.
67. Kessler M, Terramani T, Lynch G, Baudry M. A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem. 1989;52:1319-28.
68. Parsons CG, Danysz W, Quack G, et al. Novel systemically active antagonists of the glycine site of the N-methyl-D-aspartate receptor: electrophysiological, biochemical and behavioral characterization. J Pharmacol Exp Ther. 1997;283:1264-75.
69. Birch PJ, Grossman CJ, Hayes AG. Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur J Pharmacol. 1988;154:85-7.
70. Perkins MN, Stone TW. Actions of kynurenic acid and quinolinic acid in the rat hippocampus in vivo. Exp Neurol. 1985;88:570-9.
71. Hilmas C, Pereira EF, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX. The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J Neurosci. 2001;21:7463-73.
72. Fatokun AA, Smith RA, Stone TW. Resistance to kynurenic acid of the NMDA receptor-dependent toxicity of 3-nitropropionic acid and cyanide in cerebellar granule neurons. Brain Res. 2008;1215:200-7.
73. Guillemin GJ, Brew BJ. Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease. RedoxRep. 2002;7:199-206.
74. Lee do Y, Lee KS, Lee HJ, et al. Kynurenic acid attenuates MPP(+)-induced dopaminergic neuronal cell death via a Bax-mediated mitochondrial pathway. Eur J Cell Biol. 2008;87:389-97.
75. Robotka H, Nemeth H, Somlai C, Vecsei L, Toldi J. Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus. Eur J Pharmacol. 2005;513:75-80.
76. Barth MC, Ahluwalia N, Anderson TJ, et al. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem. 2009;284:19189-95.
77. Morita T, Saito K, Takemura M, et al. L-tryptophan-kynurenine pathway metabolite 3-hydroxyanthranilic acid induces apoptosis in macrophagederived cells under pathophysiological conditions. Adv Exp Med Biol. 1999;467:559-63.
78. Weber WP, Feder-Mengus C, Chiarugi A, et al. Differential effects of the tryptophan metabolite 3-hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines. Eur J Immunol. 2006;36:296-304.
79. Sekkai D, Guittet O, Lemaire G, Tenu JP, Lepoivre M. Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch Biochem Biophys. 1997;340:117-23.
80. Alberati-Giani D, Cesura AM. Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators. Amino Acids. 1998;14:251-5.
81. Lopez-Burillo S, Tan DX, Mayo JC, Sainz RM, Manchester LC, Reiter RJ. Melatonin, xanthurenic acid, resveratrol, EGCG, vitamin C and alphalipoic acid differentially reduce oxidative DNA damage induced by Fenton reagents: a study of their individual and synergistic actions. J Pineal Res. 2003;34:269-77.
82. Malina HZ, Richter C, Mehl M, Hess OM. Pathological apoptosis by xanthurenic acid, a tryptophan metabolite: activation of cell caspases but not cytoskeleton breakdown. BMC Physiol. 2001;1:7.
83. Gobaille S, Kemmel V, Brumaru D, Dugave C, Aunis D, Maitre M. Xanthurenic acid distribution, transport, accumulation and release in the rat brain. J Neurochem. 2008;105:982-93.
84. Brown JC, 3rd, Tse HW, Skifter DA, et al. [3H]homoquinolinate binds to a subpopulation of NMDA receptors and to a novel binding site. J Neurochem. 1998;71:1464-70.
85. de Carvalho LP, Bochet P, Rossier J. The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int. 1996;28:445-52.
86. Tavares RG, Tasca CI, Santos CE, et al. Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int. 2002;40:621-7.
87. Ting K, Brew B, Guillemin G. Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J Neuroinflammation. 2009;6:doi:10.1186/1742-2094-1186-1136.
88. Rios C, Santamaria A. Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem Res. 1991;16:1139-43.
89. Rodriguez-Martinez E, Camacho A, Maldonado PD, et al. Effect of quinolinic acid on endogenous antioxidants in rat corpus striatum. Brain Res. 2000;858:436-9.
90. Santamaria A, Galvan-Arzate S, Lisy V, et al. Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport. 2001;12:871-4.
91. Southgate GS, Daya S, Potgieter B. Melatonin plays a protective role in quinolinic acid-induced neurotoxicity in the rat hippocampus. J Chem Neuroanat. 1998;14:151-6.
92. Nakao N, Brundin P. Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. Neuroscience. 1997;76:749-61.
93. Nakai M, Qin ZH, Wang Y, Chase TN. Free radical scavenger OPC-14117 attenuates quinolinic acid-induced NF-kappaB activation and apoptosis in rat striatum. Brain Res Mol Brain Res. 1999;64:59-68.
94. Galarraga E, Surmeier DJ, Kitai ST. Quinolinate and kainate neurotoxicity in neostriatal cultures is potentiated by co-culturing with neocortical neurons. Brain Res. 1990;512:269-76.
95. Khaspekov L, Kida E, Victorov I, Mossakowski MJ. Neurotoxic effect induced by quinolinic acid in dissociated cell culture of mouse hippocampus. J Neurosci Res. 1989;22:150-7.
96. Kim JP, Choi DW. Quinolinate neurotoxicity in cortical cell culture. Neuroscience. 1987;23:423-32.
97. Whetsell WO, Jr., Schwarcz R. Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system. Neurosci Lett. 1989;97:271-5.
98. Giulian D, Vaca K, Noonan CA. Secretion of neurotoxins by mononuclear phagocytes infected with HIV-Science. 1990;250:1593-6.
99. Giulian D, Wendt E, Vaca K, Noonan CA. The envelope glycoprotein of human immunodeficiency virus type 1 stimulates release of neurotoxins from monocytes. Proc Natl Acad Sci U S A. 1993;90:2769-73.
100. Kerr SJ, Armati PJ, Brew BJ. Neurocytotoxity of quinolinic acid in human brain cultures. J Neurovirol. 1995;1:375-80.
101. Kerr SJ, Armati PJ, Guillemin GJ, Brew BJ. Chronic exposure of human neurons to quinolinic acid results in neuronal changes consistent with AIDS dementia complex. AIDS. 1998;12:355-63.
102. Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009;4:e6344.
103. Liang ZQ, Wang XX, Wang Y, et al. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity. Neurobiol Dis. 2005;20:562-73.
104. Pemberton L, Churchill M, Guillemin G, Gorry PR, Brew B. Involvement of S100® in HIV dementia. Submitted for publication. 2009.
105. Fulle S, Mariggio MA, Belia S, et al. Rapid desensitization of PC12 cells stimulated with high concentrations of extracellular S Neuroscience. 1999;89:991-7.
106. Mariggio MA, Fulle S, Calissano P, Nicoletti I, Fano G. The brain protein S-100ab induces apoptosis in PC12 cells. Neuroscience. 1994; 60:29-35.
107. Cammer W. Oligodendrocyte killing by quinolinic acid in vitro. Brain Res. 2001;896:157-60.
108. Fukuoka S, Ishiguro K, Yanagihara K, et al. Identification and expression of a cDNA encoding human alpha-amino-beta-carboxymuconateepsilon-semialdehyde decarboxylase (ACMSD). A key enzyme for the tryptophan-niacine pathway and "quinolinate hypothesis". J Biol Chem. 2002;277:35162-7.
109. Pucci L, Perozzi S, Cimadamore F, Orsomando G, Raffaelli N. Tissue expression and biochemical characterization of human 2-amino 3-carboxymuconate 6-semialdehyde decarboxylase, a key enzyme in tryptophan catabolism. FEBS J. 2007;274:827-40.
110. Guillemin GJ, Smith DG, Smythe GA, Armati PJ, Brew BJ. Expression of the kynurenine pathway enzymes in human microglia and macrophages. AdvExp Med Biol. 2003;527:105-12.
111. Coggan SE, Smythe GA, Bilgin A, Grant RS. Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid. J Neurochem. 2009;108:1220-5.
112. Foster AC, Vezzani A, French ED, Schwarcz R. Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci Lett. 1984;48:273-8.
113. Jhamandas K, Boegman RJ, Beninger RJ, Bialik M. Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites. Brain Res. 1990;529:185-91.
114. Guillemin GJ, Wang L, Brew BJ. Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex. J Neuroinflammation. 2005;2:16.
115. Guillemin GJ, Smythe G, Takikawa O, Brew BJ. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia. 2005;49:15-23.
116. Doraiswamy PM, Finefrock AE. Metals in our minds: therapeutic implications for neurodegenerative disorders. Lancet Neurol. 2004;3:431-4.
117. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol. 2005;146:1041-59.
118. Tomioka H, Shimizu T, Tatano Y. Effects of picolinic acid on the antimicrobial functions of host macrophages against Mycobacterium avium complex. Int J Antimicrob Agents. 2007;29:460-4.
119. Manzari B, Kudlow JE, Fardin P, et al. Induction of macrophage glutamine: fructose-6-phosphate amidotransferase expression by hypoxia and by picolinic acid. Int J Immunopathol Pharmacol. 2007;20:47-58.
120. Fernandez-Pol JA, Klos DJ, Hamilton PD. Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. Anticancer Res. 2001;21:3773-6.
121. Guillemin GJ, Kerr SJ, Brew BJ. Involvement of quinolinic acid in AIDS dementia complex. NeurotoxRes. 2005;7:103-23.
122. Kosenko E, Montoliu C, Giordano G, et al. Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells. J Neurochem. 2004;89:1101-10.
123. Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ. Mechanism for quinolinic Acid cytotoxicity in human astrocytes and neurons. Neurotox Res. 2009;16:77-86.
124. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81:247-65.
125. Munn DH, Mellor AL. IDO and tolerance to tumors. Trends Mol Med. 2004;10:15-8.
126. Guillemin GJ, Kerr SJ, Smythe GA, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78:842-53.
127. Rzeski W, Kocki T, Dybel A, et al. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in cultured cerebral cortical neurons. J Neurosci Res. 2005;80:677-82.
128. Wejksza K, Rzeski W, Okuno E, Kandefer-Szerszen M, Albrecht J, Turski WA. Demonstration of kynurenine aminotransferases I and II and characterization of kynurenic acid synthesis in oligodendrocyte cell line (OLN-93). Neurochem Res. 2005;30:963-8.
129. Ting KK, Brew B, Guillemin G. The involvement of astrocytes and kynurenine pathway in Alzheimer's disease. NeurotoxRes. 2007;12:247-62.
130. Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem. 1999;274:23223-8.
131. Chung KK, Dawson VL, Dawson TM. The role of the ubiquitinproteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 2001;24:S7-14.
132. McNaught KS, Olanow CW, Halliwell B, Isacson O, Jenner P. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci. 2001;2:589-94.
133. Gelman BB, Schuenke K. Brain aging in acquired immunodeficiency syndrome: increased ubiquitin-protein conjugate is correlated with decreased synaptic protein but not amyloid plaque accumulation. J Neurovirol. 2004;10:98-108.
134. Haorah J, Heilman D, Diekmann C, et al. Alcohol and HIV decrease proteasome and immunoproteasome function in macrophages: implications for impaired immune function during disease. Cell Immunol. 2004;229:139-48.
135. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology. 2008;5:51.
136. Zatloukal K, Stumptner C, Fuchsbichler A, et al. p62 Is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol. 2002;160:255-63.
137. Nagaoka U, Kim K, Jana NR, et al. Increased expression of p62 in expanded polyglutamine-expressing cells and its association with polyglutamine inclusions. J Neurochem. 2004;91:57-68.
138. Alirezaei M, Kiosses WB, Fox HS. Decreased neuronal autophagy in HIV dementia: a mechanism of indirect neurotoxicity. Autophagy. 2008;4:963-6.
139. Christensen PM, Gotzsche PC, Brosen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics. 1998;8:473-9.
140. Lee G, Bendayan R. Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res. 2004;21:1313-30.
141. Lam FC, Liu R, Lu P, et al. Beta-Amyloid efflux mediated by p-glycoprotein. J Neurochem. 2001;76:1121-8.
142. Lovell MA, Markesbery WR. Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. Nucleic Acids Res. 2007;35:7497-504.
143. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J. Evolution of HIV dementia with HIV infection. Int Rev Psychiatry. 2008;20:25-31.
144. Haughey NJ, Steiner J, Nath A, et al. Converging roles for sphingolipids and cell stress in the progression of neuro-AIDS. Front Biosci. 2008;13:5120-30.
145. Li W, Malpica-Llanos TM, Gundry R, et al. Nitrosative stress with HIV dementia causes decreased L-prostaglandin D synthase activity. Neurology. 2008;70:1753-62.
146. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 2006;12:1005-15.
147. Walter S, Letiembre M, Liu Y, et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem. 2007;20:947-56.
148. Richartz-Salzburger E, Batra A, Stransky E, et al. Altered lymphocyte distribution in Alzheimer's disease. J Psychiatr Res. 2007; 41:174-8.
149. Banks WA. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol. 1999;5:538-55.
150. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68:1809-14.
151. Cameron B, Landreth GE. Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis. 2009.
152. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Degradation of tryptophan in neurodegenerative disorders. Adv Exp Med Biol. 1999;467:133-8.
153. Widner B, Leblhuber F, Walli J, Tilz GP, Demel U, Fuchs D. Tryptophan degradation and immune activation in Alzheimer's disease. J Neural Transm. 2000;107:343-53.
154. Porter RJ, Lunn BS, O'Brien JT. Effects of acute tryptophan depletion on cognitive function in Alzheimer's disease and in the healthy elderly. Psychol Med. 2003;33:41-9.
155. Heyes MP, Saito K, Crowley JS, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992;115(Pt 5):1249-73.
156. Baran H, Jellinger K, Deecke L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm. 1999;106:165-181.
157. Guillemin GJ, Brew BJ, Noonan CE, Takikawa O, Cullen KM. Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol Appl Neurobiol. 2005; 31:395-404.
158. Guillemin G, Brew B, Noonan CE, Knight TG, Cullen KM. Mass spectrometric detection of quinolinic acid in microdissected Alzheimer disease plaques. International Congress Series. 2007;1304:404-8.
159. Guillemin GJ, Smythe GA, Veas LA, Takikawa O, Brew BJ. A beta 1-42 induces production of quinolinic acid by human macrophages and microglia. Neuroreport. 2003;14:2311-5.
160. Aldinio C, Aporti F, Calderini G, Mazzari S, Zanotti A, Toffano G. Experimental models of aging and quinolinic acid. Methods Find Exp Clin Pharmacol. 1985;7:563-8.
161. Mishizen-Eberz AJ, Rissman RA, Carter TL, Ikonomovic MD, Wolfe BB, Armstrong DM. Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer's disease pathology. Neurobiol Dis. 2004; 15:80-92.
162. Griffin WS, Nicoll JA, Grimaldi LM, Sheng JG, Mrak RE. The pervasiveness of interleukin-1 in Alzheimer pathogenesis: a role for specific polymorphisms in disease risk. Exp Gerontol. 2000;35:481-7.
163. de Leon MJ, Mosconi L, Li J, et al. Longitudinal CSF isoprostane and MRI atrophy in the progression to AD. J Neurol. 2007;254:1666-75.
164. Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer's amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol. 2000;130:184-208.
165. Parker WD Jr, Parks J, Filley CM, Kleinschmidt-DeMasters BK. Electron transport chain defects in Alzheimer's disease brain. Neurology. 1994;44:1090-6.
166. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789-99.
167. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy. AIDS. 1999;13:1249-1253.
168. Wiley CA, Masliah E, Morey M, et al. Neocortical damage during HIV infection. Ann Neurol. 1991;29:651-7.
169. Everall IP, Luthert PJ, Lantos PL. Neuronal loss in the frontal cortex in HIV infection. Lancet. 1991;337:1119-21.
170. Masliah E, Achim CL, Ge N, DeTeresa R, Terry RD, Wiley CA. Spectrum of human immunodeficiency virus-associated neocortical damage. Ann Neurol. 1992;32:321-9.
171. Brew BJ, Rosenblum M, Cronin K, Price RW. AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. AnnNeurol. 1995;38:563-70.
172. Kure K, Lyman WD, Weidenheim KM, Dickson DW. Cellular localization of an HIV-1 antigen in subacute AIDS encephalitis using an improved double-labeling immunohistochemical method. Am J Pathol. 1990;136:1085-92.
173. Brew BJ, Bhalla RB, Paul M, et al. Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. AnnNeurol. 1990;28:556-60.
174. Brew BJ, Bhalla RB, Fleisher M, et al. Cerebrospinal fluid beta 2 microglobulin in patients infected with human immunodeficiency virus. Neurology. 1989;39:830-4.
175. Heyes MP, Brew BJ, Martin A, et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. AnnNeurol. 1991;29:202-9.
176. Martin A, Heyes MP, Salazar AM, et al. Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals. J Neuropsychiatry Clin Neurosci. 1992;4:270-9.
177. Brouwers P, Heyes MP, Moss HA, et al. Quinolinic acid in the cerebrospinal fluid of children with symptomatic human immunodeficiency virus type 1 disease: relationships to clinical status and therapeutic response. J Infect Dis. 1993;168:1380-6.
178. Heyes MP, Brew BJ, Saito K, et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol. 1992;40:71-80.
179. Fuchs D, Moller AA, Reibnegger G, Stockle E, Werner ER, Wachter H. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr. 1990;3:873-6.
180. Huengsberg M, Winer JB, Gompels M, Round R, Ross J, Shahmanesh M. Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin Chem. 1998;44:858-62.
181. Valle M, Price RW, Nilsson A, Heyes M, Verotta D. CSF quinolinic acid levels are determined by local HIV infection: cross-sectional analysis and modelling of dynamics following antiretroviral therapy. Brain. 2004;127:1047-60.
182. Fuchs D, Gisslen M, Larsson M, Norkrans G, Hagberg L, Wachter H. Increase of tryptophan in serum and in cerebrospinal fluid of patients with HIV infection during zidovudine therapy. Adv Exp Med Biol. 1996;398:131-4.
183. Achim CL, Heyes MP, Wiley CA. Quantitation of human immunodeficiency virus, immune activation factors, and quinolinic acid in AIDS brains. J Clin Invest. 1993;91:2769-75.
184. Bara H, Hainfellner JA, Kepplinger B, Mazal PR, Schmid H, Budka H. Kynurenic acid metabolism in the brain of HIV-1 infected patients. J Neural Transm. 2000;107:1127-38.
185. Rigby M, Le Bourdelles B, Heavens RP, et al. The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain. Neuroscience. 1996;73:429-47.
186. Griffin DE, McArthur JC, Cornblath DR. Neopterin and interferon-gamma in serum and cerebrospinal fluid of patients with HIV-associated neurologic disease. Neurology. 1991;41:69-74.
187. Tyor WR, Glass JD, Griffin JW, et al. Cytokine expression in the brain during the acquired immunodeficiency syndrome. AnnNeurol. 1992;31:349-60.
188. Eugenin EA, D'Aversa TG, Lopez L, Calderon TM, Berman JW. MCP-1 (CCL2) protects human neurons and astrocytes from NMDA or HIV-tatinduced apoptosis. J Neurochem. 2003;85:1299-311.
189. Grant RS, Naif H, Thuruthyil SJ, et al. Induction of indolamine 2,3-dioxygenase in primary human macrophages by human immunodeficiency virus type 1 is strain dependent. J Virol. 2000;74:4110-5.
190. Patel CA, Mukhtar M, Pomerantz RJ. Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol. 2000;74:9717-26.
191. Magnuson DS, Knudsen BE, Geiger JD, Brownstone RM, Nath A. Human immunodeficiency virus type 1 tat activates non-N-methyl-D-aspartate excitatory amino acid receptors and causes neurotoxicity. Ann Neurol. 1995;37:373-80.
192. Cheng J, Nath A, Knudsen B, et al. Neuronal excitatory properties of human immunodeficiency virus type 1 Tat protein. Neuroscience. 1998;82:97-106.
193. Smith DG, Guillemin GJ, Pemberton L, et al. Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol. 2001;7:56-60.
194. Lipton SA. Requirement for macrophages in neuronal injury induced by HIV envelope protein gp Neuroreport. 1992;3:913-5.
195. Tai YF, Pavese N, Gerhard A, et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain. 2007;130:1759-66.
196. Pavese N, Gerhard A, Tai YF, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 2006;66:1638-43.
197. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 1986;321:168-71.
198. Schwarcz R, Whetsell WO Jr, Mangano RM. Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science. 1983;219:316-8.
199. Reynolds GP, Pearson SJ, Halket J, Sandler M. Brain quinolinic acid in Huntington's disease. J Neurochem. 1988;50:1959-60.
200. Schwarcz R, Tamminga CA, Kurlan R, Shoulson I. Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia. Ann Neurol. 1988;24:580-2.
201. Reynolds GP, Pearson SJ. Increased brain 3-hydroxykynurenine in Huntington's disease. Lancet. 1989;2:979-80.
202. Guidetti P, Schwarcz R. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv Exp Med Biol. 2003;527:137-45.
203. Guidetti P, Bates GP, Graham RK, et al. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis. 2006;23:190-7.
204. Zadori D, Klivenyi P, Vamos E, Fulop F, Toldi J, Vecsei L. Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm. 2009;116:1403-9.
205. Stoy N, Mackay GM, Forrest CM, et al. Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem. 2005;93:611-23.
206. Jauch D, Urbanska EM, Guidetti P, et al. Dysfunction of brain kynurenic acid metabolism in Huntington's disease: focus on kynurenine aminotransferases. J Neurol Sci. 1995;130:39-47.
207. Beal MF, Matson WR, Swartz KJ, Gamache PH, Bird ED. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem. 1990;55:1327-39.
208. Sapko MT, Guidetti P, Yu P, Tagle DA, Pellicciari R, Schwarcz R. Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Exp Neurol. 2006;197:31-40.
209. Sugars KL, Rubinsztein DC. Transcriptional abnormalities in Huntington disease. Trends Genet. 2003;19:233-8.
210. Giorgini F, Moller T, Kwan W, et al. Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem. 2008;283:7390-400.
211. Shaw PJ. Molecular and cellular pathways of neurodegeneration in motor neurone disease. J Neurol Neurosurg Psychiatry. 2005;76:1046-57.
212. Ilzecka J, Kocki T, Stelmasiak Z, Turski WA. Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand. 2003;107:412-8.
213. Chen Y, Stankovic R, Cullen KM, et al. The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis. Neurotox Res. 2009.
214. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009;8:382-97.
215. Schwarcz R, Kohler C. Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci Lett. 1983;38:85-90.
216. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol. 1992;32:782-8.
217. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990;54:823-7.
218. Beal MF. Mitochondrial dysfunction in neurodegenerative diseases. Biochim Biophys Acta. 1998;1366:211-23.
219. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38:1285-91.
220. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F. Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience. 1993;52:1-6.
221. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest. 2009;119:182-92.
222. Ogawa T, Matson WR, Beal MF, et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology. 1992;42:1702-6.
223. Knyihar-Csillik E, Csillik B, Pakaski M, et al. Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. Neuroscience. 2004;126:899-914.
224. Luchowski P, Luchowska E, Turski WA, Urbanska EM. 1-Methyl-4-phenylpyridinium and 3-nitropropionic acid diminish cortical synthesis of kynurenic acid via interference with kynurenine aminotransferases in rats. Neurosci Lett. 2002;330:49-52.
225. Knyihar-Csillik E, Chadaide Z, Mihaly A, Krisztin-Peva B, Fenyo R, Vecsei L. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol. 2006;112:127-37.
226. Kikuchi S, Kim SU. Glutamate neurotoxicity in mesencephalic dopaminergic neurons in culture. J Neurosci Res. 1993;36:558-69.
227. Wu HQ, Rassoulpour A, Schwarcz R. Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum. J Neural Transm. 2002;109:239-49.
228. Shytle RD, Mori T, Townsend K, et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem. 2004;89:337-43.
229. Park HJ, Lee PH, Ahn YW, et al. Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci. 2007;26:79-89.